Skip to main content
Premium Trial:

Request an Annual Quote

BGI Acquires 27 SOLiD 4 Sequencers


This story was originally published Oct. 29.

Life Technologies said last week that China's BGI has acquired 27 SOLiD 4 systems, which will allow BGI to sequence 50 whole human genomes per month.

Li Jingxiang, vice president of genomics operations for BGI, said in a statement that the SOLiDs will enable the institute to "secure sequence data for a complete whole human genome on 30x coverage that includes 100 gigabases of mapped data at an accuracy of 99.9 percent."

The new SOLiDs will join a fleet of Illumina machines at BGI. In January, the institute ordered 128 HiSeq 2000 sequencers, which have been installed over the course of the year (IS 1/12/2010).

Paul Tu, president of BGI Americas, told In Sequence in September that by the end of the year, BGI's Hong Kong location will have at least 100 Illumina HiSeq 2000 machines and 20 SOLiD instruments, while BGI's Shenzhen facility will have 37 HiSeq 2000 instruments and between 5 and 10 SOLiD instruments.

Tu said at the time that the number of SOLiDs might grow, "depending on the customer demand in human resequencing." (IS 9/21/2010)

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.